Short pressure reactivity index versus long pressure reactivity index in the management of traumatic brain injury

Erhard W. Lang, MD, PhD,¹ Magdalena Kasprzowiec, PhD,² Peter Smielewski, PhD,³ Edgar Santos, MD,⁴ John Pickard, FRCs(SN), FMedSci,³ and Marek Czosnyka, PhD³

¹Neurosurgical Associates, Red Cross Hospital, Kassel; ²Department of Neurosurgery, University of Heidelberg, Germany; ³Institute of Biomedical Engineering and Instrumentation, Wroclaw University of Technology, Wroclaw, Poland; and ⁴Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, United Kingdom

OBJECT The pressure reactivity index (PRx) correlates with outcome after traumatic brain injury (TBI) and is used to calculate optimal cerebral perfusion pressure (CPPopt). The PRx is a correlation coefficient between slow, spontaneous changes (0.003–0.05 Hz) in intracranial pressure (ICP) and arterial blood pressure (ABP). A novel index—the so-called long PRx (L-PRx)—that considers ABP and ICP changes (0.0008–0.008 Hz) was proposed.

METHODS The authors compared PRx and L-PRx for 6-month outcome prediction and CPPopt calculation in 307 patients with TBI. The PRx- and L-PRx–based CPPopt were determined and the predictive power and discriminant abilities were compared.

RESULTS The PRx and L-PRx correlation was good (R = 0.7, p < 0.00001; Spearman test). The PRx, age, CPP, and Glasgow Coma Scale score but not L-PRx were significant fatal outcome predictors (death and persistent vegetative state). There was a significant difference between the areas under the receiver operating characteristic curves calculated for PRx and L-PRx (0.61 ± 0.04 vs 0.51 ± 0.04; z-statistic = -3.26, p = 0.011), which indicates a better ability by PRx than L-PRx to predict fatal outcome. The CPPopt was higher for L-PRx than for PRx, without a statistical difference (median CPPopt for L-PRx: 76.9 mm Hg, interquartile range [IQR] ± 10.1 mm Hg; median CPPopt for PRx: 74.7 mm Hg, IQR ± 8.2 mm Hg). Death was associated with CPP below CPPopt for PRx (χ² = 30.6, p < 0.00001), and severe disability was associated with CPP above CPPopt for PRx (χ² = 7.8, p = 0.005). These relationships were not statistically significant for CPPopt for L-PRx.

CONCLUSIONS The PRx is superior to the L-PRx for TBI outcome prediction. Individual CPPopt for L-PRx and PRx are not statistically different. Deviations between CPP and CPPopt for PRx are relevant for outcome prediction; those between CPP and CPPopt for L-PRx are not. The PRx uses the entire B-wave spectrum for index calculation, whereas the L-PRx covers only one-third of it. This may explain the performance discrepancy.

http://thejns.org/doi/abs/10.3171/2014.10.JNS14602

KEY WORDS brain monitoring; cerebral autoregulation; cerebrovascular reactivity; severe head injury; outcome; cerebral perfusion pressure; traumatic brain injury

ARTERIAL blood pressure (ABP), intracranial pressure (ICP), cerebral blood flow velocity measured with transcranial Doppler ultrasonography, and cerebral microcirculation assessed by laser Doppler flow are periodical biological signals that can be continuously monitored and recorded in both routine and ICU settings by using invasive and noninvasive techniques and devices.⁵,¹²,¹⁶,³⁰,³² These biological signals will show frequency peaks within certain frequency bands.⁶,¹¹ They can be categorized into two groups: 1) the B waves that occur at approximately 0.5–3 cycles per minute, which corresponds to a frequency of 0.008–0.05 Hz;⁵,¹⁶,²³ and 2) M waves, which occur at approximately 4–9 cycles per minute, which corresponds to a frequency of 0.07–0.15 Hz.⁰,¹²,²² The 6 venti-
latory cycles per minute ventilation test is a clinical tool to create an artificial stimulus for M-wave activity.8,19

All clinical tests of cerebrovascular reactivity require a stimulus variable and a response variable.1,3,10,15,32 The stimulus is classically an increase or decrease in ABP, which can be applied via an internal stimulus—i.e., ABP-related B waves or M waves; or external—i.e., thigh cuff deflation, transient carotid occlusion, pharmacological blood pressure variations, or changes in ventilator settings. The response to the stimulus can be graded, and indices that grade magnitude and/or time can be calculated. In clinical practice these indices can be used to quantify cerebrovascular reactivity, which contributes to cerebral autoregulation. Intact, partially impaired, or completely disrupted cerebral autoregulation has been reported, and various degrees of impairment have prognostic relevance.1,3,13,17,25,32

The pressure reactivity index (PRx), which is an index calculated from a moving correlation coefficient between mean ABP and ICP, has gained wide acceptance in ICU settings, and it has generated a large number of publications.2,3,14,17,27–29 It is clinically most attractive because it does not require an external stimulus or patient manipulation, and routinely monitored data can be used for clinical research. The PRx has been reported to correlate with outcome after traumatic brain injury (TBI),14,17 and it is used for online calculation of the optimal cerebral perfusion pressure (CPPopt).2,29

The PRx is calculated from mean ABP and ICP within a frequency range of 0.003–0.05 Hz. Recently a new PRx, called long (L)-PRx, that considers slower changes in ABP and ICP (within a frequency range of 0.0008–0.008 Hz) has been introduced.27,28 Its utility and prognostic relevance have been confirmed in a small series of 18 patients with spontaneous intracranial hemorrhage,28 and in a second series of 29 patients with TBI.27

The aim of our study was to investigate, by reference to PRx performance, the utility and performance of the L-PRx for long-term outcome assessment and CPPopt calculation in a large TBI series.

Methods

We retrospectively analyzed digital recordings of ABP and ICP waveforms from 307 patients with TBI who were hospitalized and treated at the Neurocritical Care Unit at Addenbrooke’s Hospital, Cambridge University, United Kingdom, between 2003 and 2009 with the ICM+ software (http://www.neurosurg.cam.ac.uk/icmplus). The outcome assessed by the Glasgow Outcome Scale (GOS) at 6-month follow-up was available for 302 patients.

The PRx and L-PRx values were calculated as the moving linear correlation coefficients between 30 samples of time-averaged (10-second period) data points of ICP and ABP (PRx) and 20 samples of time-averaged (60-second period) data points of ICP and ABP (L-PRx; Fig. 1).

A curve-fitting method was applied to determine the CPPopt for PRx and that for L-PRx in an individual patient, as the CPP associated with the minimum value of PRx and L-PRx, respectively, when plotted against CPP (Fig. 2). In individual patients, the difference between either CPPopt for PRx or CPPopt for L-PRx and mean CPP for the whole monitoring period was calculated. Then the chi-square test was used to compare the rate of the positive (CPP > CPPopt > 0) and negative differences (CPP > CPPopt < 0) in groups of patients with severe disability and persistent vegetative state (PVS), and those who died.

Logistic regression was used to examine the association between either PRx or L-PRx and fatal outcome, which we herein define as PVS and death, with adjustment for age, CPP, and admission Glasgow Coma Scale (GCS) score. The areas under the receiver operating characteristic curves were used to compare the discriminant abilities and predictive power of both indices.

The nonparametric Mann-Whitney U-test was used to compare between the dichotomized outcome groups fatal (PVS and death) versus nonfatal (good, moderate, and severe disability) for both PRx and L-PRx. The level of significance was set at 0.05.

Computerized data monitoring that supports critical care management is standard clinical practice on the Neurosurgical ICU at Addenbrooke’s Hospital. Use of the data for anonymous audit and publications is approved by the local ethics committee.

Results

Table 1 provides an overview of patients’ demographic data, clinical variables, and outcomes. The overall median age was 36 ± 26 years (median ± interquartile range [IQR]), and 233 of the 302 patients were male (77%). There was an overall good correlation between averaged values of PRx and L-PRx (R = 0.70, p < 0.00001; Spearman test).

The PRx, age, CPP, and GCS score but not the L-PRx were significant predictors of fatal outcome (PVS and death), based on the Wald criterion (p < 0.05). A test of the full model against the constant-only model was statistically significant, indicating that the set of predictors of the PRx (p = 0.046), age (p < 0.000001), CPP (p < 0.002), and GCS score (p < 0.002) reliably distinguished between patients with fatal outcome (GOS ≤ 4) and nonfatal outcome (GOS < 4) at 6 months after discharge from hospital (χ² = 46.9, p < 0.000001 with df = 4). The logistic regression model is described by the equation:

\[
\text{Pr}(X) = \frac{e^{3.08-0.15\text{GCS}+0.04\text{Age}-0.07\text{CPP}+1.98\text{PRx}}}{1 + e^{3.08-0.15\text{GCS}+0.04\text{Age}-0.07\text{CPP}+1.98\text{PRx}}}
\]

The classification performance values for discrimination between fatal and nonfatal outcome were as follows: good accuracy (78.3%) and excellent sensitivity (95.9%), but poor specificity (25.7%). An analysis of the odds ratios (Table 2) showed that of all the predictors an increase in the PRx most significantly increases the chance of fatal outcome. Nevertheless, wide 95% confidence limits of the odds ratio for PRx might suggest low precision of this estimation.

There was a significant difference between areas under the receiver operating characteristic curves calculated for the PRx and the L-PRx (0.61 ± 0.04 vs 0.51 ± 0.04; z statistic = 3.26, p = 0.011). It suggests better ability of PRx than L-PRx to predict fatal outcome (PVS and death; Fig. 3).
Fig. 1. Chart showing an example of the PRx and L-PRx values (y axis) recorded over a 10-hour-period. Note that although the trending appears to follow a common pattern, there are several instances where PRx and L-PRx differ considerably.

Fig. 2. Plots showing PRx (A) and L-PRx (B) examples versus CPP plotted in an individual patient. The CPPopt values are 72.5 mm Hg for CPPopt-PRx (A) and 77.5 mm Hg for CPPopt–L-PRx (B). Panel C shows the percentage of time spent within individual CPP intervals.

Table 1. Demographic data, clinical variables, and outcome at 6 months in 302 patients with TBI*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total No.</th>
<th>No. Male</th>
<th>Age (yrs)</th>
<th>GCS Score</th>
<th>ICP</th>
<th>ABP</th>
<th>CPP</th>
<th>PRx</th>
<th>L-PRx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>48</td>
<td>30</td>
<td>27 ± 24</td>
<td>7 ± 4.5</td>
<td>16.6 ± 6.4</td>
<td>94.7 ± 6.5</td>
<td>77.1 ± 6.4</td>
<td>0.035 ± 0.203</td>
<td>0.020 ± 0.176</td>
</tr>
<tr>
<td>Moderate</td>
<td>79</td>
<td>66</td>
<td>29 ± 19</td>
<td>8 ± 6</td>
<td>15.7 ± 4.9</td>
<td>93.8 ± 7.8</td>
<td>77.8 ± 6.0</td>
<td>0.064 ± 0.193</td>
<td>0.038 ± 0.198</td>
</tr>
<tr>
<td>Severe</td>
<td>100</td>
<td>75</td>
<td>38 ± 24</td>
<td>5 ± 5</td>
<td>16.0 ± 5.6</td>
<td>94.6 ± 9.1</td>
<td>78.4 ± 9.2</td>
<td>0.070 ± 0.178</td>
<td>0.050 ± 0.267</td>
</tr>
<tr>
<td>PVS</td>
<td>9</td>
<td>7</td>
<td>38 ± 26</td>
<td>5 ± 5</td>
<td>15.5 ± 4.5</td>
<td>86.1 ± 11.1</td>
<td>74.2 ± 9.3</td>
<td>0.018 ± 0.044</td>
<td>0.033 ± 0.216</td>
</tr>
<tr>
<td>Dead</td>
<td>66</td>
<td>55</td>
<td>45 ± 31</td>
<td>5 ± 5</td>
<td>18.8 ± 9.0</td>
<td>96.1 ± 9.5</td>
<td>75.3 ± 11.5</td>
<td>0.140 ± 0.186</td>
<td>0.042 ± 0.237</td>
</tr>
</tbody>
</table>

* Unless otherwise noted, values are the median ± IQR. Units of measure for the ICP, ABP, and CPP: mm Hg. PRx and L-PRx are the correlation coefficients.
The CPPopt values for pooled data were higher by approximately 5 mm Hg for L-PRx than for PRx (Fig. 4). Individual CPPopt for PRx was identified in 299 of 307 patients (97.4%), and that for L-PRx was found in 300 patients. There was no statistical difference between CPPopt for PRx and L-PRx (median 74.7 mm Hg, IQR ± 8.2 mm Hg vs median 76.9 mm Hg, IQR ± 10.1 mm Hg).

Mortality was associated with a mean CPP below the CPPopt for PRx ($\chi^2 = 30.6, p < 0.00001$), whereas severe disability was associated with CPP above the CPPopt for PRx ($\chi^2 = 7.8, p = 0.005$). These relationships were not statistically significant for CPPopt calculated for L-PRx (Fig. 5).

**Discussion**

This study investigates the utility of two indices of cerebrovascular reactivity for clinical practice in patients with TBI, and it shows that both PRx and L-PRx can be calculated from monitored variables in almost all patients. Calculated from different frequencies, they correlate well, although in our particular series the PRx is superior to L-PRx for TBI outcome prediction.

In their first comparative study Santos et al. report a PRx–L-PRx correlation of $R = 0.84$, which is higher than in our study ($R = 0.7$). It must be noted, however, that their series consists of 18 patients with spontaneous intracerebral hemorrhage, which may represent a less variable clinical entity than our series of 307 patients with TBI. These numerical and etiological differences are likely to explain this slight discrepancy.

Interestingly, they also report that: “L-PRx–CPPopt was found to be the same as PRx-CPPopt in all but one patient” and recommend a larger series for confirmation of their findings. This larger series, which we present herein, now shows an approximately 5 mm Hg difference between the two indices for CPPopt calculation, which is not statistically significant, and on top of that may represent a number that we consider difficult to target and/or maintain in a clinical ICU setting.

In their second series of 29 patients with TBI they report a significant L-PRx difference between survival and death. Our large TBI series shows that the PRx is significantly higher in patients with fatal outcome (PVS and death) than in patients with nonfatal outcome (good, moderate, severe disability), which we cannot confirm for the L-PRx. This finding brings us to a previously raised issue. This particular study as well as the cited ones are not meant to enter a competition in search of the most superior outcome prediction tool or technique. We wish to stress the point that we assess the applicability and performance of indices of cerebrovascular reactivity on a given data set, for which we confirm or refute its utility.

By now researchers have identified numerous univariate-analysis patient- and treatment-associated factors that contribute to outcome, such as age, GCS and GCS subscores, injury patterns, sex, time of data acquisition, CPP, ICP, cerebral blood flow, cerebral partial pressure of oxygen, coagulation status, and so on. The specific composition of any clinical data set is therefore highly variable. This points toward the complexity of TBI, and it becomes highly difficult if not impossible to control or correct for any one of these confounding variables in outcome prediction. This answers the question why different indices perform differently in different data sets.

Based on previously published data from the Cambridge group, which were derived from a different data set, the CPPopt concept has been suggested. Steiner et al. as well as Aries et al. showed that an increasing ΔCPP/CPPopt correlated with less favorable outcome after TBI. Our study confirms the concept and utility of CPPopt. It also shows that although individual CPPopt for L-PRx and PRx were not statistically different, deviations between CPP and CPPopt for PRx are relevant for outcome prediction, whereas those between CPP and CPPopt for L-PRx are not. This once again raises the issue of the clinical utility of the indices, and it shows that the PRx offers an opportunity that the L-PRx does not.

**Table 2. Comparison of predictors of fatal outcome in patients with TBI**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCS score</td>
<td>0.90 (0.83–0.99)</td>
<td>0.86 (0.78–0.94)</td>
</tr>
<tr>
<td>Age</td>
<td>1.04 (1.02–1.05)</td>
<td>1.04 (1.03–1.07)</td>
</tr>
<tr>
<td>CPP</td>
<td>0.94 (0.91–0.98)</td>
<td>0.94 (0.90–0.98)</td>
</tr>
<tr>
<td>PRx</td>
<td>19.7 (3.18–122)</td>
<td>7.24 (1.03–50.7)</td>
</tr>
<tr>
<td>L-PRx</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS = not significant.

![FIG. 3. Plots showing better ability of PRx than L-PRx to predict fatal outcome (PVS and death). n.s. = not significant.](image-url)
In the search for an explanation of this discrepancy it becomes important to consider the physiological basis referred to in the introduction. The PRx is calculated from the frequency that represents the entire B-wave activity: 0.5–3 cycles per minute. The cycles represent the body’s intrinsic generators and a sufficient activity per cycle must be generated to evoke and calculate autoregulatory responses. The L-PRx calculation only covers the spectrum up to 1 cycle per minute (slow frequency components within the 0.5–3 cycles per minute waveband). This translates into the fact that the L-PRx uses only one-third of its potential input activity and is likely to lack essential autoregulatory-generating elements with limited cerebrovascular reactivity representation. This is likely to be the cause for the L-PRx lack of performance in this particular matter.

We also report that death is associated with a mean CPP below CPPopt for the PRx. Interestingly, severe disability is associated with a mean CPP above CPPopt for the PRx. This has been reported in an analysis of the same database at Addenbrooke’s Hospital. In a rather simple clinical interpretation, this indicates that too-high CPP produces unfavorable outcomes and that too-low CPP causes death. More detailed considerations and the discussion about this issue can be found in the original paper.

**FIG. 4.** Plots showing PRx and L-PRx versus CPP for pooled data from all 307 patients. The CPPopt for PRx (upper plot) was demonstrated at 70–75 mm Hg, whereas CPPopt for L-PRx (lower plot) was at 75–80 mm Hg.
A recent paper has taken this issue further, and it also points toward the limitations of our analysis. Johnson et al. dichotomized 107 patients with TBI, in keeping with the Marshall classification, into “diffuse” (Marshall Types I, II, and III) and “focal” (Marshall Types IV, evacuated mass lesion, and nonevacuated mass lesion) groups. They confirmed that a low PRx was significantly associated with favorable outcome for the combined and the diffuse groups. This was not confirmed for the focal group. This points toward the fact that the utility of any global index may not pick up the heterogeneity of various types of head injury patterns. This calls for a further analysis of TBI subsets to validate the utility and performance of indices of cerebrovascular reactivity for long-term outcome assessment and CPPopt calculation.

Depreitere and colleagues presented a new index called the Low-frequency Autoregulation index (LAx), where they also use minute-by-minute data of ICP and mean ABP in patients with head trauma (as in L-PRx). Their intention was to assess the vascular pressure reactivity of cerebral autoregulation with an algorithm called the Dynamic Adaptive Target of Active Cerebral AutoRegulation (DATACAR). This methodology has been tested using historical data up to 24 hours preceding the time point of interest, and allowed the identification of CPPopt with a high success rate. The time that the subjects were close to this individualized CPPopt correlated with the outcome, although for unknown reasons the authors used only the first 48 hours of monitoring information. In our opinion, CPPopt should be used to guide the whole period of intensive management, particularly through periods of secondary intracranial hypertension.

**Conclusions**

The PRx allows more precise outcome prediction than the L-PRx. Deviations from CPPopt obtained for PRx were more predictive than those calculated for L-PRx, although the individual values of CPPopt for L-PRx and PRx were not statistically different. The PRx uses the entire B-wave spectrum for index calculation, whereas the L-PRx covers only one-third of it. This may explain the performance discrepancy.

**Acknowledgments**

All authors thank the Neurocritical Care Unit staff members at Addenbrooke’s Hospital for their active involvement and support during the study.

**References**


---

**FIG. 5.** Bar graphs showing the relationship between severe disability rate (A and C) and mortality rate (B and D) for the difference between mean CPP and CPPopt calculated for the PRx (A and B) and the L-PRx (C and D). See text for values. Totals are slightly lower in this figure because data were not available in some patients.


Author Contributions
Conception and design: Smielewski, Santos, Pickard, Czosnyka. Acquisition of data: Smielewski, Pickard, Czosnyka. Analysis and interpretation of data: Kasprowicz, Smielewski, Santos, Czosnyka, Lang. Drafting the article: Lang. Critically revising the article: Lang, Kasprowicz, Smielewski, Czosnyka. Reviewed the final version of the manuscript: Lang, Santos. Approved the final version of the manuscript on behalf of all authors: Lang. Statistical analysis: Kasprowicz, Smielewski, Czosnyka. Administrative/technical/material support: Pickard. Study supervision: Pickard, Czosnyka.

Supplemental Information
Previous Presentation
This work was presented at the 15th International Conference on Intracranial Pressure and Brain Monitoring, which was held in Singapore, November 6–10, 2013.

Correspondence
Erhard W. Lang, Neurosurgery Associates, Red Cross Hospital, Bergmannstrasse 30, D-34121 Kassel, Germany. email: keeflang@online.de.